Alnylam Pharmaceuticals
Pays vs peer median
×1.50
+50% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | Tenaya Therapeutics Inc. | heart disease | discovery | $10M | $1.1B |
| 2024 | rareNeuro | Regeneron | rareNeuro | preclinical | $1.0B | $3.4B |
| 2024 | Cardiovascular RNAi programs | Tenaya Therapeutics | Heart Failure, Cardiomyopathy | preclinical | $10M | $1.1B |
How this is computed
For each Alnylam Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.611, clamped to [0.7, 1.5].